Modality
Cell Therapy
MOA
SHP2i
Target
JAK2
Pathway
Ferroptosis
FTD
Development Pipeline
Preclinical
Jul 2022
→ Sep 2031
PreclinicalCurrent
NCT04617765
2,690 pts·FTD
2022-09→2031-09·Recruiting
NCT05384477
1,054 pts·FTD
2022-07→2028-12·Completed
3,744 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-12-042.7y awayInterim· FTD
2031-09-085.4y awayInterim· FTD
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Complet…
Preclinical
Recruit…
Catalysts
Interim
2028-12-04 · 2.7y away
FTD
Interim
2031-09-08 · 5.4y away
FTD
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04617765 | Preclinical | FTD | Recruiting | 2690 | EASI-75 |
| NCT05384477 | Preclinical | FTD | Completed | 1054 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Doxacagene | Sanofi | Approved | PSMA | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Daratuximab | BioMarin | Phase 1 | PRMT5 | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | TROP-2 | |
| 369-4107 | Hansoh Pharma | Phase 2 | TNFα | |
| Talatapinarof | Samsung Biologics | Phase 1/2 | PCSK9 | |
| Teravorutinib | Illumina | Phase 2 | JAK2 |